177Lu-DOTA-EB-TATE
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for 177Lu-DOTA-EB-TATE, covering 2017-10-12 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer [Phase 1, Phase 2]